ARA-290 (Cibinetide)

Design rationale

Erythropoietin drives red cell production through a receptor homodimer, but a separate body of work described tissue-protective effects in nerve, kidney and heart that did not track with haematopoiesis. Those effects were attributed to a heterocomplex pairing the erythropoietin receptor with the beta-common receptor. ARA-290 reproduces an eleven-residue stretch of the helix-B external surface, a region facing away from the classical binding interface, in order to address the second complex selectively.

Neuropathy and pain research

Inflammation and metabolic models

Distinguishing features

The N-terminal pyroglutamate residue is a deliberate structural feature that improves resistance to aminopeptidase cleavage. Even so, the plasma half-life described in the literature is short, which is why study designs often use repeated administration schedules in animals rather than single exposures.

Scope of the evidence

Store sealed vials at −20 °C, dry and away from light, and allow them to reach room temperature before opening so no condensation reaches the cake. Reconstitution in the laboratory is normally carried out with bacteriostatic or sterile water introduced slowly against the inner vial wall, swirling gently until the solution clears; avoid vortexing, which foams and denatures peptide. Keep reconstituted material at 2–8 °C, protected from light, and prepare aliquots before any freezing step so that repeated freeze–thaw cycles do not degrade the eleven-residue chain.